Business Context and Reporting Period
Company: Akers Biosciences, Inc. (Ticker: AKER)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2020 (Event Date)
Reporting Period: Specific event date; not a periodic financial report.
Key Financial Metrics
This filing reports a capital raise event rather than operational financial performance. Key metrics related to the transaction include:
- Shares Issued: 1,366,856 shares of common stock.
- Offering Price: $3.53 per share.
- Gross Proceeds: Approximately $4.825 million (before placement agent fees and offering expenses).
- Transaction Type: Registered direct offering.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as of this date.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement with institutional and accredited investors. This transaction increases the company's share count and capital base. The offering was conducted pursuant to a shelf registration statement (File No. 333-234449) declared effective on April 7, 2020.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the completion of the offering mechanics and the filing of a prospectus supplement on May 18, 2020. No specific forward-looking guidance, strategic outlook, or risk factors are detailed within this specific 8-K text beyond the standard disclosure of the transaction.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the final net proceeds after deducting placement agent fees and offering expenses.
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Review the full Prospectus Supplement (filed May 18, 2020) for detailed use of proceeds.
- Check subsequent filings for the actual cash balance impact on the company's liquidity.